Rod MacLeod Yes. Hey, Anthony, this is Rod. The first is, your math is directionally right, using those assumptions. We do think PDN continues to be a growth driver for us. We've seen good sequential growth quarter-over-quarter with that business. We also continue to see NSBP as a growth driver and we're all seeing ourselves as well as our competitors out there, continuing to push NSBP. But fundamentally, your math is right. We're -- as Kevin mentioned, we're sitting here after two pretty strong quarters in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of (I.R.S. Employer incorporation or org ...

1Q 2023 Earnings Call Presentation A P RI L 2 6 , 2 0 2 3 Forward-Looking Statements 2 Management uses certain non-GAAP financial measures, most specifically Adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the company's operating performance period over period, analyze the underlying business trends, assess performance relative to competitors and establish operational objectives. • Stock-based compensation expense – The company excludes non-cash costs related to the company's ...

Kevin Thornal Thanks, Larry. Operator Your next question comes from the line of Bill Plovanic with Canaccord. Bill Plovanic Great. Thanks for taking my question and I echo LarryÂ's comments for both Keith and Kevin. Just my question is really going to be more on market share. As we look at this, Keith and Rod just on the numbers. It looks like the U.S. Spinal Cord business was flat, which is a great improvement when you strip out the PDN, but I am just curious when you can -- your commentary that you think ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of (I.R.S. Employer incorporation or or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Iden ...

Keith Grossman Okay. Thanks, Joanne. Why donÂ't I take the PDN Salesforce build and the search and IÂ'll let Rod take the CAGR question. So, the PDN referral Salesforce build is sort of an ongoing process. We tend to go in tranches once or a couple times a year and I – in the past, and I think this year, it'll be more of a continual building. So weÂ've come into this year with a referral sales team of little more than 50 individuals, I think, will probably exit this year with something closer to 80 to 90. A ...

Nevro Corporation (NYSE:NVRO) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Julie Dewey - Chief Corporate Communications & IR Officer Keith Grossman - Chairman, CEO & President Roderick MacLeod - CFO Conference Call Participants Simran Kaur - Piper Sandler & Co. Joanne Wuensch - Citi Devin Geiman - Nephron Research David Rescott - Truist Securities Brandon Vazquez - William Blair & Company Nathan Treybeck - Wells Fargo Securities Robert Marcus - JPMorgan Chase & Co. David ...

3Q 2022 Earnings Presentation N O VE M BER 2 , 2 0 2 2 Dania Forward-Looking Statements In addition to historical information, this presentation contains forward-looking statements reflecting the company's current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our full year 2022 financial guidance; our belief that we will continue to see a gradual overall trend of SCS market recovery, which we expect to c ...

| --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | From Recovery to | | | | | | | | Renewed Growth | | | | | | | | Canaccord Genuity Annual Growth Conference | | | | | | | | R O D M a c LEOD C H I E F F I N A N C I A L O F F I C E R A UG US T 1 0 , 2 0 2 2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Forward-Loo ...